

4TH ANTIBODY INDUSTRIAL SYMPOSIUM

EDITION 2016

Current and Next Generation Antibody Formats

July 4th - 5th, 2016
Montpellier – France

www.ais2016.insight-outside.fr

Organization by


MABimprove
LabEx Tours Montpellier

MABDESIGN

4th ANTIBODY INDUSTRIAL SYMPOSIUM

History & context

Antibody Industrial Symposium since 2013



Key figures

387 participants

30 scientific talks

157 industrials

10 plenary sessions

Come and see what's new in 2016 !

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats



2 day conference fully dedicated to Therapeutic Antibody and Immunotherapy



**Industrial
Development**

Into
Market

Promote Innovation

Share New Technologies


Contribute to Sustainable mAbs Development

Exchange Ideas and create New Partnerships

Learn about novel Antibodies

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats



DISCOVER

- What BEST is being done in the field
- From R&D to Clinical Development




LEARN

- About new antibody products
- About innovative technologies to develop mAbs



CONNECT

- And enlarge your network
- And reinforce your collaborations and partnerships



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Keynote Speakers

Plenary Sessions

StartUps Pitch
Presentations



DISCOVER

- What BEST is being done in the field
- From R&D to Clinical Development

Partnering B2B



LEARN

- About new antibody products
- About innovative technologies to develop mAbs

Sponsorship &
Exhibit
Opportunities



CONNECT

- And enlarge your network
- And reinforce your collaborations and partnerships

Networking

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Many opportunities for networking

Scientific plenary sessions

High level scientific talks

Get the latest news

Exchange with experts

B2B / Partnering

Meet new clients and partners

Build new collaborations

Pitches : New Ab formats and technology

Present your technology & know-how

Build new collaborations

Exchange with experts

mAbs Innovation in Outsourcing : Challenges & Opportunities

Get to know industry new work

Discover new opportunities to interact with big pharmas

Technology suppliers session

Learn about cutting-edge materials and technologies






Get to know how they can support your R&D








4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Program – DAY 1

Day 1 - Monday 4 th July		
08.00	Registration & welcome coffee	
09.30	Welcome Address	
09.45 – 10.30	Opening Lecture	
	Industrial Strategy on mAb Development Philippe Luscan , Member of the Executive Committee and the Global Leadership Team, Sanofi Executive Vice President, Global Industrial Affairs and President Sanofi in France, Sanofi	
10.30 – 11.15	Keynote Lecture	
	Protein Engineering Approaches to New Biologicals Andreas Plückthun , Head of Biochemistry Department University of Zurich Combined approaches from cell biology, structural biology and protein engineering are very powerful Rational approaches can be used to selectively elicit apoptosis in tumor cells Engineering approaches can be used to hit intracellular targets in a cell-selective manner	
11.15 – 12.15	Engineering New Alternative Mab Formats	
	Costimulatory T-cell engagement by the HER2/CD137 bispecific PRS-343 for tumor localized activation of the immune system Shane Olwill , Vice President & Head of Development, PIERIS Pharmaceuticals Clear outline of proof of mechanism studies and preclinical characterisation of a potential first-in-class CD137 targeted therapeutic Lessons learned from monospecific CD137 mAb based approaches which offer limited therapeutic windows due to peripheral toxicity PRS-343 is designed to promote CD137 clustering by bridging CD137-positive T cells with HER2-positive tumor cells, thereby providing a potent costimulatory signal to tumor antigen-specific T cells Show how the Anticalin platform can be used to design drugs capable of unlocking the full potential of costimulatory targets	
	Nanobodies: natural single domain antibodies Serge Muyldermans , Associate Professor & Group Leader, Vrije Universiteit Brussel Heavy chain-only antibodies in camelids and recombinant Nanobodies Nanobodies as unique research tool Nanobodies for non-invasive in vivo imaging Nanobodies as therapeutic	
12.15 – 14.00	Lunch and Poster Session	Partnering (B2B meetings)
14.00 – 14.45	Keynote Lecture	
	Bispecific Antibody Biology, Technology and Applications Paul Parren , Senior Vice President & Scientific Director, Genmab Biology of bispecific antibodies Controlled Fab-arm exchange & Duobody Technology EGFR-cMet Duobody case study Future prospects	

14.45 – 16.10	Engineering Bispecifics	
	Multi-functional DARPin™ drugs for ophthalmology and Oncology H. Kaspar Binz , Vice-President & Co-founder of Molecular Partners AG Overview on the DARPin™ platform Clinical and preclinical update on DARPin™ ophthalmology drug candidates: potential to advance ophthalmic treatments beyond current state of the art Improving cancer treatment options: preclinical and interim clinical data of multi-functional DARPin™ drugs in oncology	
	Bispecific antibodies and bifunctional antibody fusion proteins for cancer therapy Roland Kontermann , Professor, University of Stuttgart Tumor cell targeting Modulating valency Proapoptotic ligands Costimulatory ligands	
	Moving from product supplies to a global solution for your processes Hélène Panier & Christophe Grimm , Platform Marketing Manager, Sartorius Stedim Biotech Determining the optimum manufacturing process configuration for monoclonal antibodies products is no longer the challenge. COG reduction will be driven through simplifying and standardizing operations enabling the significant savings in supply chain and quality management. Platform approach for antibodies including services such as Cell Line Development, biosafety testing, flexible multi-purpose systems will enhance productivity for example by limiting the need to recruit employees with rare skill-sets. Platform Solution providers can bring more value than the sum of components and services.	
		
16.10 – 16.40	Coffee Break and Poster Session	Partnering (B2B meetings)
16.40 – 19.10	Pitch Session - New Antibody Formats & Technology	
The ISPRI Toolkit rapidly screens biologic product candidates for immunogenic potential driven by T cell epitope content and foreignness Anne De Groot , CEO, EpiVax Computational advances in antibody design: Toward improved optimization, selection and formulation David Pearlman , Senior Scientist & Manager of Biologics Software platform, Schrodinger FAM2: a novel gene transfer technology allowing spatio-temporally-regulated antibody expression for immunotherapy of cancer and infectious diseases François-Loïc Cosset , Director of Research, International Center for Infectiology Research Efficient selection of antibody fragments using phage display and exhaustive yeast two-hybrid screening Jean-Christophe Rain , Director Technological Development, Hybrigenics Services High affinity nanobodies to sense or inhibit selectively the active conformation of cellular RHO GTPases Aurélien Olichon , Associated professor, Cancer Research Center of Toulouse Aptamers, an alternative to antibodies? Jean-Jacques Toulmé , Research Director Inserm Emeritus, Inserm U1212, CNRS UMR5320, Université de Bordeaux Pre-clinical models for innovative medicine Jean-Jacques Mention , Head of Business Development, AXENIS New technology for intracellular antibody delivery Laurent Meunier , CSO, BioCellChallenge Breakthrough from the Developer's Perspective Klaus Kaiser , Head of Downstream Processing, Bayer Pharma AG Bio-arming antibodies improve their therapeutic potency Pierre Martineau , Scientist, Inserm - IRCM		
19.30 – 23.00	Gala Dinner – Faculté de Médecine de Montpellier	



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Program – DAY 2

Day 2 - Tuesday 5th July

08.00 Welcome coffee

08.30 **Keynote Lecture**



Current & Next Generation mAb Format: structural assessment and developability

Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre, Associate Editor of mAbs journal

Lesson learned from FDA and EMA approved antibodies and related products
Early structural assessment by state of the art analytical and structural methods
Critical Quality Attributes: structural and functional ranking of macro and micro-variants
De-risking the development of next generation antibodies, bispecific and bispecific-drug conjugates

09.15-10.30 **Optimize Developability & Improve Manufacturing**



Title not disclosed yet

Hervé Broly, Vice President Biotech Process Development **Merck Serono**

From Phase I to Phase II, BiSpecific mAb format, process optimization and quality improvement

Ludovic Laurent & Bruno Chedozeau, Vitry Bio R&D, **Sanofi**

Process optimization
Quality improvement
Associated analytical results



Agilent Solutions to Address Analytical Challenges in Biopharmaceutical Characterisation & Production

Donna Potts, Biopharma Market Manager – EMEA, **Agilent Technologies**

Employing automated sample preparation for improved throughput and reproducibility of mAb COAs, e.g. glycans
Increasing accessibility of mass spectrometry in Biopharma through walk-up solutions
Examples include workflows for the analysis of ADCs and a challenging PK study for Biologics

10.30 – 11.00 **Coffee Break and Poster Session**

Partnering (B2B meetings)

11.00 – 12.40

Proceeding into Clinic

Session reserved



Generation of native human bispecific IgGs facilitates progression towards the clinic

Nicolas Fischer, Head of Research Department, **NovImmune**

Development of bispecific antibodies has been hampered by expression and stability issues.
Bispecific k λ bodies benefit from an unmodified IgG structure, are expressed at multigram per liter and effectively purified using a generic downstream process.
k λ bodies support multiple modes of action and are well suited for chronic dosing.
The components of the k λ body platform as well as an update on different k λ body programs will be presented.

Title not disclosed yet



Alessandra Brescianini, European ImmunOncology medical advisor, **AMGEN**



Innate Pharma and Histalim : R&D partnership for tissue based assays, from discovery to clinical phases

Jean-Philippe Coton, CEO, **HISTALIM**

Cécile Bonnafous, R&D Director, **Innate Pharma**



More details to follow

12.40 – 13.45 **Lunch and Poster Session**

13.45 – 16.45 **mAb Innovation in Outsourcing: Opportunities & Challenges**

Partnering (B2B meetings)



Antibody patents in Europe: Possibilities and Limitations

Ulrich Storz – Patent Attorney - Michalski Hüttermann & Partner Patentanwälte mbB



innate pharma

Title not disclosed yet

Yannis Morel, Executive Vice President, Business development, **Innate Pharma**



More details to follow



More details to follow

16.45 – 17.00 **Closing Remarks, Announcement of the AIS2017**

17.00 **End of Symposium**

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Opening speaker



Philippe LUSCAN | Member of the Executive Committee and the Global Leadership Team, Sanofi
Executive Vice President, Global Industrial Affairs and President Sanofi in France

Keynote Speakers



Andreas PLÜCKTHUN | Head of the Biochemistry Department at the University of Zurich, Co-founder of MorphoSys AG, Molecular Partners AG and G7 Therapeutics

Keynote Speakers



Alain BECK | Associate Editor of *mAbs* journal, Senior Director of Department of Antibody Physico-Chemistry, Centre d'Immunologie Pierre Fabre



Paul W.H.I. Parren | Senior Vice President and Scientific Director, GenMab in the Netherlands, Professor of Molecular Immunology at Leiden University Medical Center

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Scientific Advisory Committee




Alain Beck

Associate Editor of *mAbs* journal, Senior Director of Department of Antibody Physico-Chemistry, Centre d'Immunologie Pierre Fabre



André Pèlerin

LabEx MAbImprove Deputy coordinator, Montpellier Group Leader at IRCM



Pierre Martineau

IRCM Deputy Director




Pierre Lafaye

Head of the Antibody Engineering Platform at Pasteur Institute



Léopold Bertéa

Head of Global Bioproduction Division, LFB



Ana Antunes

Science & Communication Officer, MabDesign




Thierry Wurch

Director – Immunotherapeutic programs Oncology R&D Unit Institut de Recherches SERVIER



Emmanuelle Vigne

Global Biotherapeutics Department, Sanofi



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Registration fees

Category	Early rate excluding VAT Registration before March 15th, 2016	Full rate excluding VAT
Start-up (<3 years)	€ 300	€ 400
SME (< 50 employees)	€ 450	€ 550
Mature company	€ 650	€ 750
LabEx MAbImprove members and students	€ 50	€ 75
Hospital pharmacists, other academics	€ 170	€ 220
TTO / Research institute / Cluster / Association	€ 300	€ 400

20% discount for MabDesign members

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Sponsor Opportunities

Gold

€ 15,000 (+VAT)

Your logo on AIS2016 homepage

Your logo and hyperlink on webpage dedicated to sponsors

Your logo on AIS2016 printed documents

Your logo on AIS2016 online communication

Able to put a Pull-up banner in registration area

Company flyer in the package delivered to each delegate

6 full-passes to attend AIS2016
(access to all activities)

A 12m² full-equipped booth

20 min talk in technology suppliers session*

Silver

€ 10,000 (+VAT)

Your logo on AIS2016 homepage

Your logo and hyperlink on webpage dedicated to sponsors

Your logo on AIS2016 printed documents

Your logo on AIS2016 online communication

Able to put a Pull-up banner in registration area

Company flyer in the package delivered to each delegate

4 full-passes to attend AIS2016
(access to all activities)

A 9m² full-equipped booth

10 min talk in technology suppliers session*

Bronze

€ 5,000 (+VAT)

Your logo on AIS2016 homepage

Your logo and hyperlink on webpage dedicated to sponsors

Your logo on AIS2016 printed documents

Your logo on AIS2016 online communication

Company flyer in the package delivered to each delegate


2 full-passes to attend AIS2016
(access to all activities)

A 6m² full-equipped booth

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Stand Opportunities



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Exhibitor Opportunities

Meeting Point


- € 2,000 (+VAT)
- 2m² area floor
- Electrical power
- Daily cleaning
- Bar table and 2 bar stools
- 1 full-pass (access to all activities)

Exhibitor-6m²

- € 3,000 (+VAT)
- Full-equipped booth
- 6m² area floor
- Electrical power
- Daily cleaning
- Table with 2 chairs
- 2 full-pass (access to all activities)

Exhibitor – 9m²

- € 4,000 (+VAT)
- Full-equipped booth
- 9m² area floor
- Electrical power
- Daily cleaning
- Table with 2 chairs
- 2 full-pass (access to all activities)



4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Partners Opportunities

- € 1,500 (+VAT)
- Logo in AIS2016 sponsors webpage
- Logo in AIS2016 printed documents
- 1 full-pass (access to all activities)

Supporting
Partner

- € 1,000 (+VAT)
- Logo in AIS2016 sponsor webpage

Contributing
Partner

- Logo in AIS2016 sponsor webpage

Media
Partner

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

Other Opportunities

Catering options

- Host or offer entries to the Gala Dinner
- Lunch
- Coffee Break

Advertising opportunities

- Company flyers at the Registration Counter
- Delegate bags produced and delivery by your company
- Pull-up Banners at varied locations in the venue
- Lanyards
- Pens, Notepads and USB stickers

E-mailing

- Advertising email, prepared by your company and sent to all pre-registered participants prior to the conference. A maximum of 2 emails per company will be accepted.

Prices and further details available upon request

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

About



&



- A “laboratoire d’excellence” (LabEx) dedicated to therapeutic Abs with the leitmotiv “Better antibodies, better developed, better used”
- Gathering 19 research teams and more than 200 researchers from Universities, INSERM, CNRS, INRA and hospitals
- Scientific project organized in 4 Key Questions from new target-modulating antibodies to optimization through new formats, combinations and administration route
- Coordinated by Pr. Hervé Watier (Tours) and Dr. André Pèlegri (Montpellier, deputy coordinator)
- More info : mabimprove.univ-tours.fr

- French therapeutic antibody & immunotherapy industrial organization
- Aims to structure the French industrial sector of therapeutic antibody & immunotherapy, reinforce companies competitiveness and promote the development and production of biological drugs in France
- Administration board composed of 5 bio-clusters and 3 pharmaceutical companies
- Scientific Advisory board with 8 experts on the field : Chairman – Alain Beck
- More info : www.mabdesign.fr

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

About the *Le CORUM* conference center



It is located in the center of Montpellier.
It is within walking distance of *Place de la Comédie*, the beating heart of Montpellier City.



The Exposition zone is also the lunch and coffee-break area



The auditorium Einstein - @Laurent Vilarem

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

About MONTPELLIER

AN HISTORIC CITY CENTRE

The oldest university still in activity, medieval streets... 1000 years of history.

An enchanting voyage into the heart of France's largest pedestrian centre.



Place de la Comédie, LMCommunication



Place de la Comédie by Christophe Finot / CC BY 2.5

A MEDITERRANEAN ART OF LIVING

Montpellier combines the infrastructure of a major city with a gentle art of living; colourful markets, lively café terraces, beaches just a cycle ride away and 300 days' sunshine per year!

4th ANTIBODY INDUSTRIAL SYMPOSIUM 2016

Current and Next Generation Antibody Formats

More Information and contacts



Stand Reservation

DOMINIQUE PONS, MD
dominique.pons@mabdesign.fr
Tel. (+33) 4 78 02 39 94



Logistics & Organization

ANA ANTUNES, PhD
ana-sofia.antunes@mabdesign.fr
Tel. (+33) 4 78 02 39 91